Plain-English translation of NCT05305131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding pembrolizumab and bevacizumab to standard chemotherapy can help treat advanced nasopharyngeal cancer better than chemotherapy alone. You would receive three 3-week cycles of induction chemotherapy (drugs given before radiation therapy), and your doctor would then decide whether you need concurrent chemoradiation. Half of participants will receive the standard chemotherapy combination, while the other half will receive the same chemotherapy plus the two additional medications.
Even with the best current treatment, about 30% of patients with advanced nasopharyngeal cancer experience cancer recurrence. Research suggests that adding drugs that boost the immune system and improve blood flow to tumors could help more patients survive longer and prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either standard chemotherapy or chemotherapy plus two additional drugs. Each treatment cycle lasts 3 weeks, and you would receive 3 cycles total as your induction (starting) therapy. After completing these 3 cycles, your doctor would decide whether you need concurrent chemoradiation (radiation therapy combined with chemotherapy). You would also need to provide blood samples for research studies. The entire participation could span several months depending on your follow-up care and any additional radiation therapy recommended.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Singapore